GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses

We conducted a phase II clinical trial of anti-CTLA-4 antibody (ipilimumab) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in 22 patients with metastatic melanoma and determined clinical outcomes and immunologic responses. The treatment consisted of a 3-mo induction with ipilimumab at...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncoimmunology 2016-04, Vol.5 (4), p.e1101204-e1101204
Hauptverfasser:	Kwek, Serena S., Kahn, James, Greaney, Samantha K., Lewis, Jera, Cha, Edward, Zhang, Li, Weber, Robert W., Leonard, Lonnie, Markovic, Svetomir N., Fong, Lawrence, Spitler, Lynn E.
Format:	Artikel
Sprache:	eng
Schlagworte:	CD4 CD8 clinical trial CTLA-4 effector T cells GM-CSF immunotherapy ipilimumab metastatic melanoma Original Research PD-1 T cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!